No strategy for pregnant women with glaucoma

Article

The results of a questionnaire sent out to consultant ophthalmologists in the UK, has discovered that there is no one strategy in place for the management of glaucoma in pregnant women.

The results of a questionnaire sent out to consultant ophthalmologists in the UK, has discovered that there is no one strategy in place for the management of glaucoma in pregnant women.

Daniela Vaideanu and Scott Fraser from the Sunderland Eye Infirmary, Tyne and Wear, UK sent out a questionnaire to all consultant ophthalmologists in the UK asking whether they had previous experience of treating pregnant women with glaucoma. If the respondents replied that they had, they were also asked what management they had used, what management they would currently employ and, if they were to use medical treatment, what would be their first choice agent.

Of the 605 questionnaires sent out, 282 were returned. Of the respondents, 26% had previously treated pregnant women with glaucoma. Most (71%) had continued with the therapy that the women were already on. In total, 34%, on observing the situation, decided not to treat. When asked what they would currently do in this scenario, 31% responded that they were unsure and 40% replied that they would continue the current treatment. A total of 45% of respondents said that they would use beta-blockers, should medical treatment be required, whereas 33% said they would use prostaglandins.

On review of the data, the researchers concluded that, although more than a quarter of ophthalmologists have come across the situation, there is currently no optimal strategy in place for dealing with it. They suggest that guidelines be produced based on current knowledge and modified as new evidence appears.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.